Feed

BACKGROUND Pulmonary embolism is associated with increased morbidity and mortality, yet the patient can sometimes look deceptively calm at the bedside. A normal blood pressure reading does not rule out a struggling right ventricle, and patients classified as intermediate-high-risk can deteriorate quickly. A mobile right-heart thrombus (clot-in-transit) adds another layer of urgency because embolization can be sudden and unpredictable. CASE REPORT A 45-year-old woman with a previous pulmonary embolism presented with abrupt dyspnea, tachycardia, and hypoxemia shortly after stopping apixaban. Bedside transthoracic echocardiography showed marked right ventricular dilation and a mobile right atrial thrombus consistent with clot-in-transit. Computed tomography pulmonary angiography confirmed bilateral segmental/subsegmental pulmonary embolism. Although she remained normotensive, biomarker positivity and a lactate rise suggested early hypoperfusion. After immediate anticoagulation with unfractionated heparin, the Pulmonary Embolism Response Team was activated, and, after multidisciplinary discussion, we decided to treat the patient with reduced-dose systemic alteplase (50 mg over 2 hours). The patient improved rapidly without bleeding complications and was discharged on long-term anticoagulation. She remained in excellent clinical condition at her 2-month follow-up. CONCLUSIONS This case demonstrates that in pulmonary embolism, stability is more than a blood pressure reading. The presence of right ventricular strain together with a clot-in-transit can justify immediate treatment escalation. Reduced-dose systemic thrombolysis can be a reasonable option in carefully selected patients, but decisions should remain individualized.